Cutaneous effector T cells and associated inflammatory cytokine pathways

Cutaneous effector T cells are a specialized subset of lymphocytes that home to the skin via the expression of cutaneous lymphocyte-associated antigen (CLA) to provide localized immune surveillance and defense (PubMed: 15661031). These cells differentiate into various functional subsets, including Th1, Th2, Th17, and Th22, each characterized by the production of specific inflammatory cytokines such as IFN-gamma, IL-4, IL-17, and IL-22 (PubMed: 24947698). In healthy skin, these pathways maintain a delicate balance between protection against pathogens and tissue homeostasis; however, their chronic overactivation leads to various inflammatory dermatoses (StatPearls: NBK470192). For instance, the Th17/Th22 axis is a primary driver of psoriasis, while the Th2 axis predominates in atopic dermatitis (PubMed: 25903339). Modern dermatological therapeutics target this system by using monoclonal antibodies to neutralize specific cytokines or small molecules to inhibit the JAK/STAT signaling cascade, thereby dampening the inflammatory response and restoring skin integrity (PubMed: 31553483).

Other names

Skin-homing T cellsCutaneous lymphocyte-associated antigen (CLA)+ T cellsTh1/Th2/Th17/Th22 skin axisDermal effector T-cell pathways

Therapeutic agents modulate these pathways by neutralizing specific pro-inflammatory cytokines (e.g., IL-17, IL-23, IL-4, IL-13), blocking their respective receptors, or inhibiting intracellular signaling mediators like Janus kinases (JAKs) to prevent the transcription of inflammatory genes and the recruitment of effector T cells to the skin.